A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to FcƔRIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.

Trial Profile

A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to FcƔRIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs BI 1206 (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 19 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 07 Jul 2016 Status changed from planning to not yet recruiting.
    • 16 Dec 2015 According to a BioInvent media release, the company plans to submit a Clinical Trial Application for this trial to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in April 2016. The trial will begin after all the regulatory and ethical approvals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top